Ibaraki, Japan

Tatsuto Fukushima

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Tatsuto Fukushima: A Pioneer in Heterodiazinone Derivatives

Introduction

Tatsuto Fukushima is a notable inventor based in Ibaraki, Japan. With one patent to his name, he has made significant contributions to the field of chemistry, particularly with his work on heterodiazinone derivatives. His role at Eisai Company, Limited positions him among the key innovators shaping the future of pharmaceuticals.

Latest Patents

Fukushima's most recent patent focuses on heterodiazinone derivatives, a class of compounds that may have various applications in the pharmaceutical industry. The specific details of this patent highlight his innovative approach to developing new chemical entities that could potentially lead to therapeutic advancements.

Career Highlights

Currently employed at Eisai Company, Limited, a prominent organization in the pharmaceutical sector, Tatsuto Fukushima has established himself as a key figure in research and development. His dedication to innovation has led to the exploration of new pharmaceutical compounds, strengthening the company's position in the market.

Collaborations

Throughout his career, Tatsuto has collaborated with talented colleagues, including Koichi Ito and Noritaka Kitazawa. These partnerships reflect the collaborative spirit within Eisai Company, Limited, fostering a conducive environment for innovation and advancement in scientific research.

Conclusion

Tatsuto Fukushima's contributions to the field of chemistry and his innovative work on heterodiazinone derivatives reinforce the importance of research and development in the pharmaceutical industry. With his ongoing efforts at Eisai Company, Limited, Fukushima continues to pave the way for future innovations that could significantly impact healthcare and medical treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…